Country
United Kingdom
ViiV Healthcare has received US approval for a combination drug to treat HIV-1. Cabenuva (cabotegravir and rilpivirine) is the first injectable, long-acting regimen for the treatment of the viral infection in adults who are on a stable antiretroviral regimen.
Full text available to subscribers only. Click here for information on subscribing to MedNous.